CAPA-IVM Culture With Low Oxygen Tension

June 9, 2025 updated by: Mỹ Đức Hospital
Capacitation in-vitro maturation (CAPA-IVM) has recently been advanced in culturing oocytes from the germinal vesicle (GV) stage following mild or no controlled ovarian stimulation. Recent research suggested that O2 concentration may significantly regulate oocyte maturation and early embryo development through hypoxia-inducible factor (HIF). Nonetheless, it has been challenging to create the environmental culture conditions for addressing the optimal number of oocytes and the highest possibility of embryo development since consensus on the oxygen (O2) concentration index in the IVM culture environment has not been reached. Based on the outcomes of atmospheric O2 concentration (20%) and low O2 concentration (5%) during CAPA-IVM culture in mice, it has been hypothesized that a 5% O2 was the optimal culture condition for the pre-IVM step. A 20% O2 was more suitable for the IVM culture step. Therefore, this study is designed to enhance the CAPA-IVM culture system, improving treatment efficiency and providing various benefits for patients undergoing assisted reproductive technology.

Study Overview

Detailed Description

Capacitation in-vitro maturation (CAPA-IVM) has recently been advanced in culturing oocytes from the germinal vesicle (GV) stage. This approach is a modified version of conventional in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), following mild stimulation or no controlled ovarian stimulation occurred. Specifically, IVM can be indicated for patients diagnosed with polycystic ovary syndrome (PCOS), a higher number of secondary follicles (constituting nearly 15% of total patients), and treat a range of patients with the risks of ovarian hyperstimulation, venous thromboembolism or ovarian torsion. Additionally, CAPA-IVM helps shorten treatment time, is less expensive, and upgrades patient convenience without multiple follow-up examinations. The live birth rate after the first embryo transfer in the CAPA-IVM group was 35.2%, which was not statistically significantly different from the IVF group at 43.2% (risk difference -8.1%; 95% confidence interval from -16.6% to 0.5%). However, the number of high-quality embryos in each cycle and the cumulative clinical pregnancy rate in CAPA-IVM were still lower than in cIVF.

Moreover, further investigation should be considered due to the lack of high-quality evidence of concurrent reports. Therefore, improving the oocyte maturation conditions in CAPA-IVM to harvest the optimal number of oocytes and the highest possibility of embryo development is essential. Many studies conducted on both animal and human models have demonstrated that the effectiveness of CAPA-IVM depends on various factors. Among these, the environmental culture conditions such as oxygen (O2) concentration play a crucial role in producing healthy mature oocytes. O2 is a vital physical and chemical component of the fallopian tube, uterus and ovarian follicle, it is closely related to metabolic activity, oocyte maturation, and early embryo development. Recent research suggested that O2 concentration may significantly regulate oocyte maturation and early embryo development through hypoxia-inducible factor (HIF). A consensus on the O2 concentration index in the IVM culture environment has not been reached. Oocyte-embedded culture systems have been commonly used in two O2 concentrations, 5% and 20% worldwide. In the human body, cumulus-oocyte complexes (COCs) mature in conditions with low O2 concentrations ranging from 2% to 9%.

Conversely, COCs are exposed to an atmospheric O2 concentration of 20% during IVM manipulation and culture. Although the concentration of 5% mimics the most proper environment in the fallopian tube and uterus, the 20% O2 is widely applied in IVM techniques. The use of high concentrations facilitates a better progression of differentiation processes and increases the maturation rate of oocytes. However, some referential frames indicated that a 20% O2 may pose a risk of reactive oxidative stress (ROS), leading to an imbalance in the ratio of pro-oxidants to antioxidants, resulting in cellular damage. Furthermore, real-time respiration analysis of oocytes cultured at 5% O2 is similar to in vivo-developed oocytes but induced cellular activity and oxygen consumption at 20% O2. The impact of atmospheric O2 concentration (20%) and low O2 concentration (5%) during CAPA-IVM culture in mice shown in the study of Vrije Universiteit Brussel (VUB) - Belgium that the respiratory capability of COCs cultured at 5% O2 was relatively similar to COCs developing and maturing in vivo.

Nonetheless, COCs cultured at 20% O2 increased respiratory activity and oxygen consumption remarkably. The study observed that pre-IVM culture of COCs at 20% O2 caused developmental disruptions. Also, the result was unfavorable if mouse COCs were cultured at the IVM step with 5% O2. Based on these analyses, the researchers hypothesized that a 5% O2 was the optimal culture condition for the pre-IVM step, while a 20% O2 was more relevant to the IVM culture step. Combining these findings with results from VUB and characteristics of the differentiation process in CAPA-IVM oocytes, this study is divided into two main groups, including 5% pre-IVM and 20% IVM versus 20% pre-IVM and IVM) and demonstrates whether this hypothesis should be applied CAPA-IVM in human. The enhancement of the CAPA-IVM culture system leads to improved treatment efficiency of this technique and provides various benefits for patients undergoing assisted reproductive technology.

Study procedure:

Screening for eligibility

  • This trial will be conducted at My Duc Hospital, Ho Chi Minh City, Viet Nam.
  • Women who are potentially eligible will be provided information about the trial at the time of IVM treatment indication.
  • Screening for eligibility will be performed on the day of the first visit when the IVM treatment is indicated.
  • Patients will be provided information related to the study together with the informed consent documents. Signed informed consent forms will be obtained by the investigators from all women before the enrolment.

Oocytes will be divided into 2 groups:

Group 1 (includes 2 subgroups: 1A and 1B): Air Oxygen Concentration CAPA-IVM culture T = Total number of oocytes after OR and there are two subgroups.

The number of oocytes is divided below:

If T is an even number:

  • Number of oocytes in Group 1A: One oocyte.
  • Number of oocytes in Group 1B: T1B = (T-2)/2.

If T is an odd number:

  • Number of oocytes in Group 1A: One oocyte.
  • Number of oocytes in Group 1B: T1B = ([T-1]-2)/2. One oocyte remainder of the first patient will be assigned to group 1B, and the remainder of the next patient will be assigned to group 2B. Continuing to do so sequentially for the next remainder.

Group 2 (includes 2 subgroups: 2A and 2B): Low Oxygen Concentration CAPA- IVM culture T = Total number of oocytes after OR and there are two subgroups.

The number of oocytes is divided below:

If T is an even number:

  • Number of oocytes in Group 2A: One oocyte.
  • Number of oocytes in Group 2B: T2B = (T-2)/2.

If T is an odd number:

  • Number of oocytes in Group 2A: One oocyte.
  • Number of oocytes in Group 2B: T2B = ([T-1]-2)/2. One oocyte remainder of the first patient will be assigned to group 1B, and the remainder of the next patient will be assigned to group 2B. Continuing to do so sequentially for the next remainder.

Group 1A, 2A: Collecting after capacitation: oocyte and cumulus cell.

Group 1B, 2B: Collecting after capacitation: spent media, blank well. Collecting after maturation: spent media, cumulus cell, blank well.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Ho Chi Minh City, Vietnam
        • My Duc Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 18-42 years of age
  • Diagnosed with polycystic ovary syndrome according to the Rotterdam criteria (2003)
  • Indicating CAPA-IVM treatment
  • Having at least 40 antral follicles in two ovaries by transvaginal ultrasound at the time of CAPA-IVM indication
  • Agreeing to have frozen embryo transfer
  • Agreeing to participate in the trial

Exclusion Criteria:

  • Cycles with oocyte donation, preimplantation Genetic Testing (PGT)
  • Couples with severe male factor (sperm concentration <5 million/ml, motility < 10%), surgical sperm retrieval
  • Previous history of unexplained immature oocytes after IVF treatment
  • Uterine abnormalities

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Air Oxygen Concentration CAPA-IVM culture
Half of the COCs will be cultured in the CAPA step and IVM step at 37 degrees Celsius in air oxygen concentration (20%) and 6% carbon dioxide.
  • Group 1A: COC will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.
  • Group 1B: COCs will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and in the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius.
Active Comparator: Low Oxygen Concentration CAPA-IVM culture
Half of the COCs will be cultured in the CAPA step at a low oxygen concentration (5%) and IVM step at an air oxygen concentration (20%); all two steps combine 6% carbon dioxide at 37 degrees Celsius.
  • Group 2A: COC will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.
  • Group 2B: COCs will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maturation rate
Time Frame: Two day after oocyte retrieval
The oocyte maturation rate was usually defined by MII oocyte number divided by total COCs number
Two day after oocyte retrieval

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mode of delivery
Time Frame: At birth
Vaginal delivery, C-section (elective, suspected fetal distress, non-progressive labor)
At birth
Total number of oocytes retrieval
Time Frame: On the day of oocyte retrieval
Counting the number of oocytes retrieved
On the day of oocyte retrieval
Number of patients with no oocyte retrieved
Time Frame: On the day of oocyte retrieval
Counting the number of patients with no oocyte retrieved
On the day of oocyte retrieval
Number of MII oocytes
Time Frame: Two day after oocyte retrieval
The oocyte maturation was usually defined by MII oocyte number
Two day after oocyte retrieval
Number of GV oocytes
Time Frame: Two day after oocyte retrieval
Counting the number of GV oocytes
Two day after oocyte retrieval
Number of patients with no matured oocyte
Time Frame: Two day after oocyte retrieval
Counting the number of patients with no matured oocyte
Two day after oocyte retrieval
Number of 2PN oocytes
Time Frame: 16-18 hours after ICSI
Number of zygotes with 2 pronuclei after ICSI
16-18 hours after ICSI
Fertilization rate
Time Frame: 16-18 hours after ICSI
Number of fertilized oocytes / number of oocytes inseminated
16-18 hours after ICSI
Abnormal fertilization rate
Time Frame: 16-18 hours after ICSI
The percentage of zygotes with 1,3, or 4 pronuclei after ICSI / number of oocytes inseminated
16-18 hours after ICSI
Number of patients with no day-3 embryo
Time Frame: Five day after oocyte retrieval
Counting the number of patients with no embryo
Five day after oocyte retrieval
Number of day-3 embryos
Time Frame: Three days after intra-cytoplasmic sperm injection
Counting the number of day-3 embryos at 64±2h after ICSI
Three days after intra-cytoplasmic sperm injection
Number of good quality Day-3 embryos
Time Frame: Three days after intra-cytoplasmic sperm injection
Number of grade 1 and grade 2 day-3 embryos
Three days after intra-cytoplasmic sperm injection
Number of frozen day-3 embryos
Time Frame: Three days after ICSI
Counting the numer of frozen day-3 embryos
Three days after ICSI
Number of blastocyst (day 5 or day 6 embryo)
Time Frame: Five or six days after ICSI
Counting the number of blastocyst at 114±2h/140±2h after ICSI
Five or six days after ICSI
Number of patients with no blastocyst
Time Frame: Five or six days after ICSI
Counting the number of patients with no blastocyst
Five or six days after ICSI
Number of good quality blastocysts
Time Frame: Five days after intra-cytoplasmic sperm injection
Number of grade 1 and grade 2 blastocysts
Five days after intra-cytoplasmic sperm injection
Number of frozen blastocysts
Time Frame: Three days after ICSI
Counting the numer of frozen blastocysts
Three days after ICSI
Number of embryos transferred
Time Frame: On the day of embryo transfer
Total embryos transferred
On the day of embryo transfer
Quality of embryos transferred (Grade 1, Grade 2, Grade 3)
Time Frame: On the day of embryo transfer
The quality of transferred embryo is classified according to Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology, 2011; D. Gardner, 1999; D. K. Gardner & Schoolcrati, 1999
On the day of embryo transfer
Positive pregnancy test rate
Time Frame: 11 days after the day of blastocyst transfer and 13 days after the day of day-3 embryo transfer
Positive pregnancy test defined as serum human chorionic gonadotropin level greater than 25 mIU/mL
11 days after the day of blastocyst transfer and 13 days after the day of day-3 embryo transfer
Implantation rate
Time Frame: At 3 weeks after embryo transfer after the completion of the embryo transfer
Implantation rate is explained as the number of gestational sacs per number of embryos transferred.
At 3 weeks after embryo transfer after the completion of the embryo transfer
Clinical pregnancy rate
Time Frame: 5 weeks after embryo transfer
Diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy at 6 weeks or more after the onset of last menstrual period. In addition to intra-uterine pregnancy, it includes a clinically documented ectopic pregnancy
5 weeks after embryo transfer
Ectopic pregnancy rate
Time Frame: 3 weeks after embryo transfer
A pregnancy outside the uterine cavity, diagnosed by ultrasound, surgical visualization or histopathology
3 weeks after embryo transfer
Ongoing pregnancy rate
Time Frame: 10 weeks after embryo transfer
Ongoing pregnancy is defined as pregnancy with a detectable heart rate at 12 weeks' gestation or beyond.
10 weeks after embryo transfer
Miscarriage <12 weeks rate (Early miscarriage)
Time Frame: 2-10 weeks after embryo transfer
Spontaneous loss of pregnancy up to 12 weeks of gestation is referred to as an early
2-10 weeks after embryo transfer
Miscarriage <22 weeks rate (late miscarriage)
Time Frame: At >10 to 20 weeks after the transfer
Spontaneous loss of pregnancy between 12 to 22 weeks is termed as late miscarriage
At >10 to 20 weeks after the transfer
Live birth rate
Time Frame: At 22 weeks of gestation
Live birth is defined as the complete expulsion or extraction from a woman of a product of fertilization, after 22 completed weeks of gestational age; which, after such separation, breathes or shows any other evidence of life, such as heartbeat, umbilical cord pulsation or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut or the placenta is attached. A birth weight of 500 grams or more can be used if gestational age is unknown. Twins counted as one live birth.
At 22 weeks of gestation
Multiple pregnancy rate
Time Frame: 4 weeks after embryo transfer
Defined as the presence of more than one gestational sac at early pregnancy ultrasound (6-9 weeks gestation)
4 weeks after embryo transfer
Multiple delivery rate
Time Frame: At 22 weeks' gestation
Defined as the complete expulsion or extraction from a woman of more than one fetus, after 22 completed weeks of gestational age, irrespective of whether it is a live birth or stillbirth
At 22 weeks' gestation
Gestational age at birth
Time Frame: At birth
Calculated by gestational age of all live births
At birth
Birth weight
Time Frame: At the time of delivery
in grams; of singletons and twins
At the time of delivery
Very low birth weight rate
Time Frame: At birth
Birth weight less than 1.500 g
At birth
Low birth weight rate
Time Frame: At birth
Birth weight less than 2.500 g
At birth
High birth weight rate
Time Frame: At birth
Implies growth beyond an absolute birth weight, historically 4.000 g or 4.500 g, regardless of the gestational age
At birth
Very high birth weight rate
Time Frame: At birth
Birth weight over than 4.500 g for women with diabetes, and a threshold of 5000 g for women without diabetes
At birth
Small for gestational age rate
Time Frame: At birth
Large for gestational age was defined as a birth weight below the 10th percentile
At birth
Large for gestational age rate
Time Frame: At birth
Large for gestational age was defined as a birth weight above the 90th percentile
At birth
Hypertension in pregnancy rate
Time Frame: At 20 weeks of gestation or beyond
Comprising pregnancy-induced hypertension (PIH), pre-eclampsia (PET), eclampsia, and HELLP syndrome.
At 20 weeks of gestation or beyond
Gestational diabetes mellitus rate
Time Frame: At 24 to 28 weeks of gestation

Diagnosed according to the latest version of ADA guidelines. a 75-g OGTT, with plasma glucose measurement when patient is fasting and at 1 and 2 h, at 24-28 weeks of gestation in women not previously diagnosed with diabetes.

  • Fasting: 92 mg/dL (5.1 mmol/L)
  • 1 h: 180 mg/dL (10.0 mmol/L)
  • 2 h: 153 mg/dL (8.5 mmol/L)
At 24 to 28 weeks of gestation
Still birth rate
Time Frame: After 20 completed weeks of gestational age
defined as the death of a fetus prior to the complete expulsion or extraction from its mother after 20 completed weeks of gestational age. The death is determined by the fact that, after such separation, the fetus does not breathe or show any other evidence of life, such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles. It includes deaths occurring during labor
After 20 completed weeks of gestational age
Premature birth rate
Time Frame: On the day of delivery
Defined as delivery at <24, <28, <32, <37 completed weeks. A birth that takes place after 22 weeks and before 37 completed weeks of gestational age.
On the day of delivery
Antepartum haemorrhage rate
Time Frame: At birth
Defined as bleeding from or into the genital tract, occurring from 24 weeks of pregnancy and prior to the birth of the baby.
At birth
Major congenital abnormalities rate
Time Frame: At birth
Structural, functional, and genetic anomalies, that occur during pregnancy, and identified antenatally, at birth, or later in life, and require surgical repair of a defect, or are visually evident, or are life-threatening, or cause death. Any congenital anomaly will be included as followed definition of congenital abnormalities in Surveillance of Congenital Anomalies by Division of Birth Defects and Developmental Disabilities, NCBDDD, Centers for Disease Control and Prevention (2020).
At birth
Neonatal mortality rate
Time Frame: between eight and 28 days after delivery
Neonatal mortality defined as the death of a live-born baby within 28 days of birth. This can be divided into early neonatal mortality, if death occurs in the first seven days after birth, and late neonatal if death occurs between eight and 28 days after delivery
between eight and 28 days after delivery
NICU admission rate
Time Frame: At birth
Counting number of babies admited to neonatal intensive care unit
At birth
Reason for NICU admission
Time Frame: At birth
Respiratory distress, Intraventricular Hemorrhage, Necrotizing enterocolitis, Sepsis
At birth

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lan N Vuong, MD, PhD, University of Medicine and Pharmacy at Ho Chi Minh City

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 13, 2024

Primary Completion (Actual)

July 11, 2024

Study Completion (Actual)

June 1, 2025

Study Registration Dates

First Submitted

March 26, 2024

First Submitted That Met QC Criteria

April 10, 2024

First Posted (Actual)

April 16, 2024

Study Record Updates

Last Update Posted (Actual)

June 12, 2025

Last Update Submitted That Met QC Criteria

June 9, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 03/24/DD-BVMD

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on In Vitro Fertilization

Clinical Trials on Air Oxygen Concentration CAPA-IVM culture

Subscribe